Issue link: https://www.e-digitaleditions.com/i/1218534
30 March 2020 Tablets & Capsules ings and conferences, with planning for the first conference at the facility already underway. "Our strategic partnership offers the possibility for both companies to take advantage of state-of-the-art equipment and a wealth of shared knowledge," says Cashmore. "It cre- ates a unique opportunity, where we are able to carry out joint research projects throughout the manufactur- ing process, and we hope to launch our first publications later this year." Positioned for growth The capital investment program was intended to meet both exist- ing and emerging client needs. The increased efficiencies and capacities will support existing client projects, while the new technologies, such as the granulation suite, will attract new projects. "This positions Parsolex as a top contract manufacturer in the pharmaceutical industry and allows them to deliver a high degree of quality to their customers as well as providing a great showcase facility for us," says Cashmore. Implementing the expansion while preserving cGMP capabilities to ensure that existing client proj- ects could continue uninterrupted has required a high degree of coor- dination between Parsolex and ven- dor partners such as Syntegon. The company plans to recommission the site by the end of the second quarter of 2020. "Feedback from our existing cli- ents has been overwhelmingly positive," says Chang, "with a signif- icant increase in new collaboration requests received in 2020. Both exist- ing and potential clients are inter- ested in scheduling site visits." Parsolex West Lafayette, IN 765 464 8414 www.parsolexinc.com Syntegon Minneapolis, MN 763 424 4700 www.syntegon.com "Recording many process parame- ters allows us to define critical and non-critical events during develop- ment. Collecting as much data as possible during development usually leads to a more successful scale up." Partnering for success Parsolex's relationship with Syn- tegon will go beyond just the pur- chase of equipment. Parsolex antici- pates the collaboration between the two companies will advance phar- maceutical development and manu- facturing as well as help address its clients' needs. While the nature of the partnership continues to evolve, discussions have included research collaborations and technical meet- pharma solids at Syntegon. "After meeting with them, we were able to come up with the best possible solutions to give them the utmost f l e x i b i l i t y f o r m a n u f a c t u r i n g a range of batch sizes and different drug delivery technologies." The data collected by the new equipment provides valuable infor- mation to enhance a formulation's success during scale up and commer- cialization—for example, enabling process parameters that enhance tableting robustness while maintain- ing bioavailability. "The modular data acquisition sys- tems record every parameter within a batch, which can then be evaluated for root-cause analysis," says Chang. Photo 3: A Solidlab 2 drum coater in the new film-coating suite provides easy scale-up of production parameters for cosmetic and functional film coating.